Stay updated with breaking news from Owner Mati. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK and OXFORD, England, June 7, 2022 /PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, today ann...
/PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, today announced Chairman and CEO Mark Penn will join The Oxford...
In Mati Therapeutics, Inc. v. Ocular Therapeutix, Inc., the Federal Circuit issued a Rule 36 opinion affirming the Patent Trial and Appeal Board's ("PTAB's") Final Written Decision ("FWD") holding all challenged claims unpatentable.
In Mati Therapeutics, Inc. v. Ocular Therapeutix, Inc., the Federal Circuit issued a Rule 36 opinion affirming the Patent Trial and Appeal Board’s PTAB’s Final Written Decision FWD holding all challenged claims unpatentable.